Last reviewed · How we verify

EV/DNG (Qlaira, BAY86-5027) — Competitive Intelligence Brief

EV/DNG (Qlaira, BAY86-5027) (EV/DNG (Qlaira, BAY86-5027)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oral contraceptive (combined estrogen-progestin). Area: Contraception / Women's Health.

phase 3 Oral contraceptive (combined estrogen-progestin) Estrogen receptor, progesterone receptor Contraception / Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

EV/DNG (Qlaira, BAY86-5027) (EV/DNG (Qlaira, BAY86-5027)) — Bayer. EV/DNG is an estradiol valerate and dienogest combination oral contraceptive that prevents ovulation through hormonal suppression.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
EV/DNG (Qlaira, BAY86-5027) TARGET EV/DNG (Qlaira, BAY86-5027) Bayer phase 3 Oral contraceptive (combined estrogen-progestin) Estrogen receptor, progesterone receptor
Tibolone (Livial) Tibolone (Livial) Wyeth is now a wholly owned subsidiary of Pfizer marketed Selective tissue estrogenic activity regulator (STEAR); synthetic steroid Estrogen receptor, progesterone receptor, androgen receptor
fenofibrate and tibolone fenofibrate and tibolone Keogh Institute for Medical Research marketed Fibrate + Selective Estrogen Receptor Modulator (SERM) PPAR-α (fenofibrate); Estrogen receptor, progesterone receptor, androgen receptor (tibolone)
Ethinyl estradiol / dienogest Ethinyl estradiol / dienogest Helsinki University Central Hospital marketed Combined oral contraceptive Estrogen receptor, progesterone receptor
Oral contraceptives cyclic Oral contraceptives cyclic University of Athens marketed Hormonal contraceptive Estrogen receptor, Progesterone receptor
Tibolone plus Xiangshao granules Tibolone plus Xiangshao granules Peking Union Medical College Hospital marketed Hormone replacement therapy (HRT) / Selective tissue estrogenic activity regulator (STEAR) Estrogen receptor, Progesterone receptor, Androgen receptor
ethinyl estradiol and cyproterone acetate ethinyl estradiol and cyproterone acetate S.C.B. Medical College and Hospital marketed Combined oral contraceptive with anti-androgenic activity Estrogen receptor, progesterone receptor, androgen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oral contraceptive (combined estrogen-progestin) class)

  1. Bayer · 3 drugs in this class
  2. Organon and Co · 2 drugs in this class
  3. Teva Pharmaceuticals USA · 2 drugs in this class
  4. University of Colorado, Denver · 1 drug in this class
  5. Oregon Health and Science University · 1 drug in this class
  6. Helsinki University Central Hospital · 1 drug in this class
  7. Ironwood Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EV/DNG (Qlaira, BAY86-5027) — Competitive Intelligence Brief. https://druglandscape.com/ci/ev-dng-qlaira-bay86-5027. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: